Results 11 to 20 of about 196,808 (340)
A potential biomarker of cognitive impairment: The olfactory dysfunction and its genes expression
Annals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1884-1897, December 2022., 2022 Abstract Objective Accumulation evidence has reported that olfactory impairment may be an essential clinical marker and predictor of mild cognitive impairment or Alzheimer's disease. Method Participants were enrolled in the population‐based, prospective study in Fuxin county, Liaoning province, China between 2019 and 2021.
Jiayi Song +11 more
wiley +1 more source
Aberrant functional connectivity within the basal ganglia of patients with Parkinson's disease
NeuroImage: Clinical, 2015 Resting state functional MRI (rs-fMRI) has been previously shown to be a promising tool for the assessment of early Parkinson's disease (PD). In order to assess whether changes within the basal ganglia network (BGN) are disease specific or relate to ...
Michal Rolinski +8 more
doaj +1 more source
Noradrenaline and Parkinson's Disease [PDF]
Frontiers in Systems Neuroscience, 2011 Parkinson's disease (PD) is characterized by the degeneration of dopamine (DA) neurons in the substantia nigra pars compacta, and motor symptoms including bradykinesia, rigidity, and tremor at rest. These symptoms are exhibited when striatal dopamine concentration has decreased by around 70%.
Claire eDelaville +3 more
openaire +5 more sources
Parkinson’s Disease and Autophagy [PDF]
Parkinson's Disease, 2012 It is generally accepted that a correlation between neurodegenerative disease and protein aggregation in the brain exists; however, a causal relationship has not been elucidated. In neurons, failure of autophagy may result in the accumulation of aggregate-prone proteins and subsequent neurodegeneration.
Ana María Sánchez-Pérez +5 more
openaire +5 more sources
Stem Cell Reports, 2016 Heterozygous mutations in the glucocerebrosidase gene (GBA) represent the strongest common genetic risk factor for Parkinson's disease (PD), the second most common neurodegenerative disorder.
Hugo J.R. Fernandes +19 more
doaj +1 more source
Frontiers in Neuroanatomy, 2015 Immunohistochemistry (IHC) is a valuable method for identifying discrete neurochemical molecules by the interaction of target antigens with validated antibodies tagged with a visible label (e.g., peroxidase).
Satoshi eGoto +6 more
doaj +1 more source
The heterogeneity of Parkinson’s disease
Journal of Neural Transmission, 2023 AbstractThe heterogeneity of Parkinson’s disease (PD), i.e. the various clinical phenotypes, pathological findings, genetic predispositions and probably also the various implicated pathophysiological pathways pose a major challenge for future research projects and therapeutic trail design.
Ullrich Wüllner +7 more
openaire +5 more sources
Predicting motor, cognitive & functional impairment in Parkinson's
Annals of Clinical and Translational Neurology, 2019 Objective We recently demonstrated that 998 features derived from a simple 7‐minute smartphone test could distinguish between controls, people with Parkinson's and people with idiopathic Rapid Eye Movement sleep behavior disorder, with mean sensitivity ...
Christine Lo +11 more
doaj +1 more source
Putaminal mosaic visualized by tyrosine hydroxylase immunohistochemistry in the human neostriatum.
Frontiers in Neuroanatomy, 2016 Among the basal ganglia-thalamocortical circuits, the putamen plays a critical role in the ‘motor’ circuits that control voluntary movements and motor learning.
Ryoma eMorigaki, Satoshi eGoto
doaj +1 more source
Impact of Neu-botulinumtoxinA on the Severity and Quality of Life of Cervical Dystonia Patients
Tremor and Other Hyperkinetic Movements, 2016 Background: Cervical dystonia (CD) is a debilitating neurological disorder that may gravely affect a patient’s quality of life (QoL). Botulinum toxin treatment has been approved as a first-line treatment for this condition.
Priya Jagota +7 more
doaj +1 more source